A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

A.W. Tolcher, D.I. Quinn, A. Ferrari, F. Ahmann, G. Giaccone, T. Drake, A. Keating, J.S. de Bono

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)968-9U9
JournalAnnals of Oncology
Issue number4
Publication statusPublished - 2012

Cite this